The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ Q4 2025 earnings at ($0.56) EPS and FY2025 earnings at ($2.21) EPS. Apellis Pharmaceuticals Stock PerformanceShares of APLS stock opened at $23.10 on Wednesday. Apellis Pharmaceuticals has a 52 week low of $16.10 and a 52 week high of $35.72. Further ReadingReceive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.